LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

16.58 1.72

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

16.15

Max

16.78

Galvenie mērījumi

By Trading Economics

Ienākumi

-70M

-67M

Pārdošana

-2.1M

20M

P/E

Sektora vidējais

48.528

106.172

Dividenžu ienesīgums

0.48

Peļņas marža

-330.585

Darbinieki

243

EBITDA

327K

5.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

-1.96% downside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.31%

Nākamie ieņēmumi

2025. g. 1. dec.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-9.6M

342M

Iepriekšējā atvēršanas cena

14.86

Iepriekšējā slēgšanas cena

16.58

Ziņu noskaņojums

By Acuity

12%

88%

8 / 374 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 20. nov. 23:07 UTC

Tirgus saruna

Evidence Of Broad Australian Economic Upswing Mounts -- Market Talk

2025. g. 20. nov. 22:22 UTC

Tirgus saruna

Auckland Airport Has Edge Over Transurban In Infrastructure Stocks -- Market Talk

2025. g. 20. nov. 22:08 UTC

Tirgus saruna

Revenues of Texas Battery Projects Drop Sharply -- Market Talk

2025. g. 20. nov. 21:57 UTC

Peļņas

Walmart Reports Strong Sales Growth, Raises Outlook -- 5th Update

2025. g. 20. nov. 21:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2025. g. 20. nov. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 20. nov. 21:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2025. g. 20. nov. 21:50 UTC

Tirgus saruna
Peļņas

Financial Services Roundup: Market Talk

2025. g. 20. nov. 21:31 UTC

Peļņas

Nvidia's Strong Results Show AI Fears Are Premature -- Update

2025. g. 20. nov. 21:23 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

2025. g. 20. nov. 21:07 UTC

Peļņas

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

2025. g. 20. nov. 21:06 UTC

Peļņas

Webull 3Q Rev $156.9M >BULL

2025. g. 20. nov. 21:06 UTC

Peļņas

Webull 3Q EPS 7c >BULL

2025. g. 20. nov. 21:05 UTC

Peļņas

Intuit 1Q Sales Jump, CFO Cites AI Demand From Mid-Sized Businesses -- Interview

2025. g. 20. nov. 21:04 UTC

Peļņas

Mid-Sized Businesses Want to Automate Tasks With AI, Intuit CFO Says >INTU

2025. g. 20. nov. 21:04 UTC

Peļņas

Intuit's AI Offerings Attracted More Mid-Sized Businesses in 1Q, CFO Says >INTU

2025. g. 20. nov. 21:04 UTC

Peļņas

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Sees 2Q Rev $4.52B-$4.55B >INTU

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Sees FY26 GAAP Operating Income $5.78B to $5.86B

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Sees 2Q Adj EPS $3.63-Adj EPS $3.68 >INTU

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Expects FY26 Global Business Solutions Rev Growth of 15.5% to 16.5%, Excluding Mailchimp

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Expects FY26 Consumer Rev Growth of 8% to 9%

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Expects FY26 Global Business Solutions Rev Growth of 14% to 15%

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Backs FY26 Rev $21B-$21.19B >INTU

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Backs FY26 Adj EPS $22.98-Adj EPS $23.18 >INTU

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit 1Q Consumer Rev $894M

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Sees 2Q EPS $1.76-EPS $1.81 >INTU

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Backs FY26 Guidance

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit Backs FY26 EPS $15.49-EPS $15.69 >INTU

2025. g. 20. nov. 21:00 UTC

Peļņas

Intuit 1Q Global Business Solutions Rev $3B

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

-1.96% uz leju

Prognoze 12 mēnešiem

Vidējais 16 USD  -1.96%

Augstākais 16 USD

Zemākais 16 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

2

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

8 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat